TABLE 3.

Cohort of 177 subjects with HBV who developed HCC while not on NAs

Variable	Compensated cirrhosis	Decompensated cirrhosis	No cirrhosis	p‐Values b
Not on NAs	127/177 (72%)	26/177 (15%)	24/177 (13%)	<0.001, <0.001
HBV DNA > 2000	4	0	5	1, 0.005
HBV DNA < 2000	8	0	2	0.3, 0.7
HBV DNA not detected	115	26	17	0.2, 0.01
ALT > 2× ULN a	46 M, 25 F	9 M, 7 F	10 M, 3 F	1, 0.7, 0.4, 0.6
ALT < 2× ULN a	44 M, 12 F	9 M, 1 F	5 M, 6 F	1, 0.2, 0.7, 0.04
ALT < 35 M, 25 F	4 M, 2 F	0 M, 0 F	4 M, 0 F	1, 0.2, 1, 1
ALT < 40	11	2	6	1, 0.03
Met AASLD 2018 criteria for NA therapy	14	26	4	<0.001, 0.5
ALD	38	7	3	0.8, 0.09
HCV	16	3	1	1, 0.3
NAFLD	27	1	2	0.05, 0.2
On NAs	89 of 209 (43%)	76 of 209 (36%)	44 of 209 (21%)	0.4, <0.001

Abbreviations: F, female; M, male; ULN, upper limit of normal.

^a ALT > 70 for males and >50 for females.

^b p‐Values comparing decompensate cirrhosis with compensated cirrhosis and no cirrhosis with compensated cirrhosis, respectively.